Equities

Nuo Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AURX:QBB

Nuo Therapeutics Inc

Actions
  • Price (USD)1.60
  • Today's Change0.00 / 0.00%
  • Shares traded19.32k
  • 1 Year change+34.45%
  • Beta-0.2414
Data delayed at least 15 minutes, as of Feb 13 2026 19:39 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. It has commercialized cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. Its commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The Aurix System produces a platelet-rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. The Aurix PRP comprises a natural, endogenous complement of protein and non-protein signal molecules that are believed to contribute to effective healing.

  • Revenue in USD (TTM)2.61m
  • Net income in USD-2.43m
  • Incorporated1998
  • Employees--
  • Location
    Nuo Therapeutics Inc8285 EL RIO, SUITE 190HOUSTON 77054United StatesUSA
  • Phone+1 (832) 236-9060
  • Fax+1 (240) 499-2690
  • Websitehttps://www.nuot.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Adicet Bio Inc0.00-115.01m67.43m152.00--0.3356-----20.22-20.220.0020.980.00----0.00-59.52-36.24-66.08-39.41-------813.80----0.0088------17.90--32.77--
TuHURA Biosciences Inc0.00-43.77m68.61m19.00--3.51-----1.60-1.600.000.32730.00----0.00-286.97---456.76-------------9.010.0286--------------
Coeptis Therapeutics Holdings Inc500.99k-11.28m69.15m5.00--5.97--138.02-3.47-3.470.14762.010.0433--11.65100,198.00-118.13-42.24-167.86-44.3272.96---2,727.81-----73.660.0224------53.85------
Gain Therapeutics Inc0.00-19.39m69.62m23.00--11.02-----0.6364-0.63640.000.16430.00----0.00-153.07-79.58-234.03-95.32-------19,975.78---33.790.067---100.00--8.34--10.39--
XBiotech Inc0.00-29.16m71.34m88.00--0.427-----0.9566-0.95660.005.480.00----0.00-15.25-7.74-16.08-8.02-------187.68----0.00-------56.90--44.92--
Maia Biotechnology Inc0.00-22.34m72.95m13.00--1,628.72-----0.7504-0.75040.000.00120.00----0.00-212.50-208.29-602.02-373.18------------0.00-------17.61------
ImageneBio Inc0.00-46.14m73.13m15.00--0.523-----8.11-8.110.0012.510.00----0.00-29.23-29.58-31.29-33.67-------407.25----0.00---100.00--27.77------
Seres Therapeutics Inc351.00k5.39m74.91m103.0014.051.667.76213.410.58920.58920.04044.990.0022----3,407.773.35-42.444.59-55.22----1,536.75-367.23----0.00------33.85---17.63--
Nuo Therapeutics Inc2.61m-2.43m77.25m--------29.58-0.0517-0.05170.0555-0.00881.434.195.32---133.29-121.45-289.99-243.0570.3878.52-93.06-424.191.00-17,110.33----124.3456.3426.73------
Tenax Therapeutics Inc0.00-43.33m77.92m4.00--0.7663-----1.13-1.130.0016.290.00----0.00-42.77-99.65-44.80-118.65------------0.00-------128.28------
Medicinova Inc257.92k-12.01m78.63m13.00--1.78--304.88-0.2449-0.24490.00530.89640.0049----19,840.00-22.73-15.56-24.08-16.17-----4,656.61-1,144.98----0.00---100.00---28.91---39.68--
Ibio Inc500.00k-20.11m79.10m20.00--0.8277--158.21-1.44-1.440.02322.770.0113--15.3825,000.00-45.35-30.90-50.81-37.76-----4,021.60-2,374.12----0.0127--77.78-24.57-19.00---57.50--
Champions Oncology Inc58.42m2.49m81.24m213.0035.1019.4820.431.390.16670.16674.140.30032.11--5.31274,291.108.78-4.6733.91-11.6650.1147.284.16-2.79----0.0327--13.5412.13164.61---29.41--
Pyxis Oncology Inc2.82m-97.09m82.81m44.00--1.20--29.37-1.58-1.580.04571.110.0187----64,090.91-64.53-47.22-74.33-53.450.00---3,442.77-2,233.63----0.0006-------4.80------
eXoZymes Inc0.00-8.34m84.00m31.00--15.61-----1.76-1.760.000.64080.00----0.00-147.87---393.50--------------0.0217-------187.55------
Data as of Feb 13 2026. Currency figures normalised to Nuo Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

2.15%Per cent of shares held by top holders
HolderShares% Held
Deerfield Management Co. LPas of 30 Sep 20241.03m2.14%
Ancora Private Wealth Advisors LLCas of 30 Sep 20254.70k0.01%
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.